Crispr Therapeut Stock Price, News & Analysis

CRISPR Therapeutics (Nasdaq: CRSP) will participate in the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021, at 2:30 p.m. ET. The event aims to showcase the company's advancements in gene-based medicines for serious diseases using its CRISPR/Cas9 platform. A live webcast will be available on the company's website, with a replay accessible for 14 days post-event. CRISPR Therapeutics specializes in various therapeutic areas, including oncology and rare diseases, and collaborates with leading firms like Bayer and Vertex Pharmaceuticals.

CRISPR Therapeutics (Nasdaq: CRSP) reported strong financial results for Q2 2021, highlighting a net income of $759.2 million, a significant increase from a $79.7 million loss in Q2 2020. The revenue surge to $900.2 million was primarily due to a $900 million upfront payment from Vertex following their collaboration amendment. The company has dosed over 45 patients with CTX001 in ongoing trials for sickle cell disease and beta thalassemia, with enrollment completion expected in Q3 2021. Additionally, CTX130 received Orphan Drug Designation for T-cell lymphoma.

CRISPR Therapeutics (CRSP) has announced a strategic partnership with Capsida Biotherapeutics to develop gene editing therapies targeting familial amyotrophic lateral sclerosis (ALS) and Friedreich’s ataxia. CRISPR will lead the Friedreich’s ataxia program, while Capsida will focus on ALS. The collaboration combines CRISPR's gene-editing technology with Capsida's advanced AAV engineering capabilities, potentially enhancing therapeutic efficacy. Both companies can co-develop and share commercialization costs and profits from their respective programs.

Vertex Pharmaceuticals and CRISPR Therapeutics announced positive results from their investigational CRISPR/Cas9 gene-editing therapy, CTX001, in treating transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD). Data from 22 patients indicated sustained treatment responses, with all TDT patients transfusion-free and SCD patients free from vaso-occlusive crises. The therapy aims to provide a one-time functional cure for these conditions. Ongoing trials are expected to finalize regulatory discussions soon.

CRISPR Therapeutics (Nasdaq: CRSP) has announced participation in three virtual investor conferences in June 2021. The events include the Jefferies Virtual Healthcare Conference on June 1 at 1:00 p.m. ET, the William Blair 41st Annual Growth Stock Conference on June 3 at 12:20 p.m. ET, and the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8 at 3:00 p.m. ET. Live webcasts of these presentations will be accessible on the company's website, and recordings will be available for 14 days post-event.

Vertex Pharmaceuticals and CRISPR Therapeutics announced the acceptance of two abstracts for presentation at the EHA 2021 Virtual Congress. The studies focus on CTX001, a gene-editing therapy for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta-Thalassemia (TDT). Both abstracts detail safety and efficacy results from ongoing clinical trials, with data on patients showing promising follow-up outcomes. CTX001 aims to alleviate severe symptoms by increasing fetal hemoglobin levels, potentially reducing transfusion needs and sickle crises.

CRISPR Therapeutics and Nkarta have announced a strategic partnership to co-develop gene-edited cell therapies for cancer. The collaboration will focus on two chimeric antigen receptor (CAR) NK cell product candidates targeting CD70 and a novel NK+T product. Nkarta obtains a license for CRISPR gene editing technology for its NK cell therapies. Both companies will equally share R&D costs and profits, with a three-year exclusivity period for allogeneic, gene-edited NK cells. This partnership aims to accelerate the development of new cancer therapies, leveraging their expertise.

CRISPR Therapeutics (Nasdaq: CRSP) announced participation in two virtual investor conferences. The Truist Securities Life Sciences Summit is set for May 5, 2021, at 11:20 a.m. ET. Following that, the 2021 Bank of America Healthcare Conference will occur on May 12, 2021, at 2:00 p.m. ET. Live webcasts will be available on the company's website, with replays archived for 14 days post-presentation. CRISPR Therapeutics focuses on gene-based medicines, leveraging its proprietary CRISPR/Cas9 technology across various disease areas.

CRISPR Therapeutics (Nasdaq: CRSP) announced a Trials in Progress poster presentation for its ongoing Phase 1 CARBON trial at the American Society of Clinical Oncology Annual Meeting. The presentation will cover the safety and efficacy of CTX110™, an allogeneic CAR-T investigational therapy targeting CD19, for treating relapsed or refractory B-cell malignancies. The virtual event will occur from June 4 to 8, 2021, with the poster session scheduled for 9:00 AM ET on June 4.